Piramal Pharma Intrinsic Value
Piramal Pharma (PPLPHARMA) median intrinsic value is ₹169.20 from 4 valuation models (range ₹104–₹169), vs current price ₹208.16 — -18.7% downside (Trading Above Median Value), margin of safety -23.0%. See PPLPHARMA P/B ratio to compare market price against book value per share.
PPLPHARMA Valuation Methods Summary — DCF, Graham Number & P/E
Piramal Pharma intrinsic value across 4 models vs current price ₹208.16 — upside/downside and value range per method. Check Piramal Pharma market worth to track the company's total market size over time.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹123.03 | ₹110.73 - ₹135.33 | -40.9% | Book Value/Share: ₹61.51, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹169.46 | ₹152.51 - ₹186.41 | -18.6% | Revenue/Share: ₹84.73, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹103.69 | ₹93.32 - ₹114.06 | -50.2% | EBITDA: ₹1376.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹169.20 | ₹135.36 - ₹203.04 | -18.7% | CF Growth: 15.0%, Discount: 15% |
PPLPHARMA Intrinsic Value vs Market Price — All Valuation Models
Piramal Pharma fair value range ₹104–₹169 vs current market price ₹208.16 across 4 valuation models. For current market price and key ratios, visit Piramal Pharma share price screener.
PPLPHARMA Intrinsic Value Analysis — Undervalued or Overvalued?
Piramal Pharma median intrinsic value ₹169.20, current price ₹208.16 — Trading Above Median Value by 18.7%, margin of safety -23.0%.
What is the intrinsic value of PPLPHARMA?
Based on our comprehensive analysis using 4 different valuation methods, the estimated intrinsic value of Piramal Pharma (PPLPHARMA) is ₹169.20 (median value). With the current market price of ₹208.16, this represents a -18.7% variance from our estimated fair value.
The valuation range spans from ₹103.69 to ₹169.46, indicating ₹103.69 - ₹169.46.
Is PPLPHARMA undervalued or overvalued?
Based on our multi-method analysis, Piramal Pharma (PPLPHARMA) appears to be trading above median value by approximately 18.7%.
PPLPHARMA Financial Health — Key Ratios vs Industry Benchmarks
Piramal Pharma financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 1.43 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Return on Equity | -0.4% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 10.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.63x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
PPLPHARMA Cash Flow Quality — Operating & Free Cash Flow
Piramal Pharma operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹1,653 Cr | ₹1,243 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹892 Cr | ₹648 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹1,005 Cr | ₹797 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹484 Cr | ₹-183 Cr | Positive Operating Cash Flow | 6/10 |
| March 2022 | ₹766 Cr | ₹-103 Cr | Positive Operating Cash Flow | 6/10 |